Myriad Genetics (MYGN) Current Deferred Revenue (2011 - 2022)

Myriad Genetics has disclosed Current Deferred Revenue across 12 years of filings, most recently posting $200000.0 for Q3 2022.

• In Q3 2022, Current Deferred Revenue fell 98.26% year-over-year to $200000.0; the TTM figure through Sep 2022 stood at $200000.0 (down 98.26% YoY), while the FY2021 annual figure was $5.2 million, down 84.1% from the prior year.
• Current Deferred Revenue retreated to $200000.0 in Q3 2022, from $300000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for MYGN reached as high as $32.8 million in Q2 2020 and fell as low as $200000.0 in Q3 2022.
• The 5-year median for Current Deferred Revenue is $2.6 million (2018), against an average of $10.2 million.
• Annual changes were most pronounced in 2020 — Current Deferred Revenue soared 1438.1% — and 2022, when it plunged 98.67%.
• A 5-year view of Current Deferred Revenue shows it stood at $2.4 million in 2018, then soared by 50.0% to $3.6 million in 2019, then soared by 808.33% to $32.7 million in 2020, then plunged by 84.1% to $5.2 million in 2021, then slumped by 96.15% to $200000.0 in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $200000.0, $300000.0, and $700000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.